Ignite Creation Date:
2024-05-05 @ 5:03 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00371345
Status:
COMPLETED
Last Update Posted:
2011-04-26
First Post:
2006-09-01
Brief Title:
Study of Dasatinib BMS-354825 in Patients With Advanced EstrogenProgesterone Receptor-positive ERPR or Her2Neu-positive Her2NeuBreast Cancer
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
Phase II Study of Dasatinib BMS-354825 for Advanced EstrogenProgesterone Receptor-Positive or Her2Neu-Positive Breast Cancer
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced ERPR or Her2neu breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None